We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abbott posted Q2 gross profit of $6.29B, up 8.9% year over year, with margin expansion to 56.4%.
Strong growth in ABT's Medical Devices and Nutrition drove a favorable product mix and higher-margin sales.
FX tailwinds, and reduced COVID testing drag reinforced ABT's margin gains despite macro issues.
In the second quarter, Abbott Laboratories (ABT - Free Report) posted gross profit of $6.29 billion, up 8.9% year over year despite a 5.4% increase in the cost of products sold (excluding amortization expense). This led to a gross margin expansion of 79 basis points (bps) to 56.4%, backed by a favorable product mix shift toward higher-margin businesses, particularly within its Medical Devices segment, where double-digit growth in diabetes care, structural heart, and electrophysiology contributed meaningfully.
The strong uptake of Libre CGM, AVEIR leadless pacemaker, and structural heart products — TriClip, Amulet and MitraClip — helped enhance pricing leverage and operational efficiency. Continued demand for Adult Nutrition products, Ensure and Glucerna, supported a richer-margin portfolio within the Nutrition business.
Additionally, improved foreign exchange conditions, with a weaker U.S. dollar versus prior expectations, provided a modest tailwind. In lieu of this, foreign exchange had a favorable year-over-year impact of 0.5% on second-quarter sales.
Continued cost discipline in manufacturing, combined with lower COVID testing drag and productivity gains across the supply chain, further supported the 79-basis-point year-over-year improvement in gross margin. These factors reinforced the company’s ability to drive profitability despite macro headwinds such as tariffs and selective pricing pressures in China’s diagnostics market.
ABT’s Peer Performance
Thermo Fisher’s (TMO - Free Report) gross margin of 41.2% in the second quarter contracted 83 basis points (bps) year over year. The contraction was due to a transition in its revenue mix as COVID-related revenues continued to decline. This created a tougher year-over-year comparison despite healthy growth in core businesses like Bioproduction, Analytical Instruments and Pharma Services. Additionally, macro headwinds, including inflationary pressures on raw materials and international conflicts causing disruption in global supply chains, negatively impacted profitability.
Boston Scientific’s (BSX - Free Report) gross margin in the second quarter contracted 152 basis points (bps) year over year to 67.7%. This decline was primarily due to inventory charges linked to the global discontinuation of its ACURATE valve. Excluding this one-time impact, underlying gross margin performance remained strong, supported by continued growth in high-margin areas such as electrophysiology, structural heart and neuromodulation.
ABT Price Performance
In the past year, Abbott’s shares have surged 16.8%, outperforming the industry’s 4.1% growth. The S&P 500 composite grew 15.6% in the same period.
Image Source: Zacks Investment Research
Discounted Valuation
ABT currently trades at a forward 12-month Price-to-Sales (P/S) of 4.88X compared with the industry average of 5.61X.
Image Source: Zacks Investment Research
ABT Stock Estimate Trend
In the past 30 days, ABT’s EPS estimate has remained unchanged for 2025 and 2026.
Image: Bigstock
What's Driving Abbott's Gross Margin Growth Amid Macro Issues
Key Takeaways
In the second quarter, Abbott Laboratories (ABT - Free Report) posted gross profit of $6.29 billion, up 8.9% year over year despite a 5.4% increase in the cost of products sold (excluding amortization expense). This led to a gross margin expansion of 79 basis points (bps) to 56.4%, backed by a favorable product mix shift toward higher-margin businesses, particularly within its Medical Devices segment, where double-digit growth in diabetes care, structural heart, and electrophysiology contributed meaningfully.
The strong uptake of Libre CGM, AVEIR leadless pacemaker, and structural heart products — TriClip, Amulet and MitraClip — helped enhance pricing leverage and operational efficiency. Continued demand for Adult Nutrition products, Ensure and Glucerna, supported a richer-margin portfolio within the Nutrition business.
Additionally, improved foreign exchange conditions, with a weaker U.S. dollar versus prior expectations, provided a modest tailwind. In lieu of this, foreign exchange had a favorable year-over-year impact of 0.5% on second-quarter sales.
Continued cost discipline in manufacturing, combined with lower COVID testing drag and productivity gains across the supply chain, further supported the 79-basis-point year-over-year improvement in gross margin. These factors reinforced the company’s ability to drive profitability despite macro headwinds such as tariffs and selective pricing pressures in China’s diagnostics market.
ABT’s Peer Performance
Thermo Fisher’s (TMO - Free Report) gross margin of 41.2% in the second quarter contracted 83 basis points (bps) year over year. The contraction was due to a transition in its revenue mix as COVID-related revenues continued to decline. This created a tougher year-over-year comparison despite healthy growth in core businesses like Bioproduction, Analytical Instruments and Pharma Services. Additionally, macro headwinds, including inflationary pressures on raw materials and international conflicts causing disruption in global supply chains, negatively impacted profitability.
Boston Scientific’s (BSX - Free Report) gross margin in the second quarter contracted 152 basis points (bps) year over year to 67.7%. This decline was primarily due to inventory charges linked to the global discontinuation of its ACURATE valve. Excluding this one-time impact, underlying gross margin performance remained strong, supported by continued growth in high-margin areas such as electrophysiology, structural heart and neuromodulation.
ABT Price Performance
In the past year, Abbott’s shares have surged 16.8%, outperforming the industry’s 4.1% growth. The S&P 500 composite grew 15.6% in the same period.
Image Source: Zacks Investment Research
Discounted Valuation
ABT currently trades at a forward 12-month Price-to-Sales (P/S) of 4.88X compared with the industry average of 5.61X.
Image Source: Zacks Investment Research
ABT Stock Estimate Trend
In the past 30 days, ABT’s EPS estimate has remained unchanged for 2025 and 2026.
Image Source: Zacks Investment Research
ABT stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.